摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3S)-5-methyl-3-propan-2-yl-2,3-dihydro-1,4-oxazin-6-one | 1355545-50-4

中文名称
——
中文别名
——
英文名称
(3S)-5-methyl-3-propan-2-yl-2,3-dihydro-1,4-oxazin-6-one
英文别名
——
(3S)-5-methyl-3-propan-2-yl-2,3-dihydro-1,4-oxazin-6-one化学式
CAS
1355545-50-4
化学式
C8H13NO2
mdl
——
分子量
155.197
InChiKey
BBECVOQDJJCDGE-SSDOTTSWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    38.7
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    (3S)-5-methyl-3-propan-2-yl-2,3-dihydro-1,4-oxazin-6-one2-异氰基-1-吗啉-4-基-3-苯基丙烷-1-酮苯膦酸 作用下, 以 2,2,2-三氟乙醇 为溶剂, 反应 1.25h, 以87%的产率得到(3S,5S)-3-(4-benzyl-5-morpholinooxazol-2-yl)-5-isopropyl-3-methylmorpholin-2-one
    参考文献:
    名称:
    新型催化体系下α-异氰乙酰胺与手性环亚胺的Ugi型缩合反应
    摘要:
    开发了一种新型的α-异氰基乙酰胺与手性环亚胺的催化Ugi-型缩合反应,首次利用苯基亚磷酸和三氟乙醇的结合促进了α-异氰基乙酰胺的Ugi-型缩合反应。在这种新的催化体系下,以环状亚胺为相对惰性底物的反应进行得很好,并以高收率和立体选择性合成了手性3-恶唑基-吗啉/哌嗪-2-one衍生物。此外,最初尝试通过用马来酸酐处理将缩合产物转化为新型稠合三环结构。
    DOI:
    10.1055/s-0032-1316549
点击查看最新优质反应信息

文献信息

  • An Asymmetric Ugi Three-Component Reaction Induced by Chiral Cyclic Imines: Synthesis of Morpholin– or Piperazine–Keto-carboxamide Derivatives
    作者:Deguang Zhu、Liang Xia、Li Pan、Sheng Li、Ruijiao Chen、Yongren Mou、Xiaochuan Chen
    DOI:10.1021/jo2021967
    日期:2012.2.3
    4-oxazin-2-one substrates, as preformed cyclic aldimines and ketoimines, were employed to develop a new asymmetric Ugi three-component reaction for the first time. The Ugi reaction of the imines, isocyanides, and carboxylic acids opens an efficient access to novel morpholin-2-one-3-carboxamide compounds. The chiral imines showed promising stereoinduction for the new chiral center of the Ugi products, and
    一系列手性5,6-二-1,4-恶嗪-2-底物,如预先形成的环状醛亚胺亚胺,首次用于开发新的不对称Ugi三组分反应。亚胺异氰酸酯羧酸的Ugi反应使人们可以有效地获得新型的吗啉-2-二-3-甲酰胺化合物。手性亚胺对Ugi产品的新手性中心显示出有希望的立体诱导,并且在大多数情况下获得了主要的反式异构体。添加一些路易斯酸或质子酸可以进一步提高非对映选择性,但通常会导致总收率下降。Ugi-3CR可以扩展到ketopiperazine-2-carboxamide衍生物的立体选择性合成。
  • Catalytic Ugi-Type Condensation of α-Isocyanoacetamide and Chiral Cyclic Imine: Access to Asymmetric Construction of Several Heterocycles
    作者:Liang Xia、Sheng Li、Ruijiao Chen、Kai Liu、Xiaochuan Chen
    DOI:10.1021/jo4000702
    日期:2013.4.5
    Several novel heterocycles have been constructed asymmetrically on the basis of a catalytic Ugi-type condensation of α-isocyanoacetamide and chiral cyclic imine. The combination of phenylphosphilic acid and trifluoroethanol is exploited to promote an Ugi-type reaction with α-isocyanoacetamide for the first time. By means of this reaction, chiral 3-oxazolyl morpholin-2-one/piperazin-2-one derivatives
    在α-异基乙酰胺和手性环状亚胺的催化Ugi型缩合的基础上,已经不对称地构建了几种新的杂环。首次利用磷酸三氟乙醇的组合促进与α-异基乙酰胺的Ugi型反应。通过该反应,以高收率和优异的立体选择性合成手性的3-恶唑吗啉-2-酮/哌嗪-2-生物。作为富电子的杂二,这些缩合产物通过适当的亲二体如马来酸酐和不饱和酰经多米诺法处理而进一步转化为稠合的三环骨架。而且,由异基乙酰胺亚胺马来酸酐一锅三组分合成手性三环骨架也是可行的。
查看更多

同类化合物

乙基6H-1,2-恶嗪-3-羧酸酯 6-乙氧基-6H-1,2-恶嗪-3-甲醛 6-乙氧基-3-苯基-6H-1,2-恶嗪 5-甲氧基-3,6-二氢-2H-[1,4]恶嗪 5-乙氧基-3,6-二氢-2H-1,4-恶嗪 5,6-二氢-2H-1,4-恶嗪-3-胺 4H-1,4-恶嗪 4-(叔丁氧羰基)-4H-[1,4]恶嗪 3H-咪唑并[2,1-c][1,4]恶嗪 3-甲基-5-苯基-2H-1,4-恶嗪 3,5-二苯基-2H-1,4-恶嗪 3,5,5,6-四甲基-5,6-二氢-2H-1,4-恶嗪-2-酮 2H-[1,4]恶嗪并[3,4-b][1,3]恶嗪 2H-1,4-恶嗪 2H-1,4-噁嗪-2-酮,5,6-二氢-5-(1-甲基乙基)-3-苯基-,(S)- 2H-1,4-噁嗪-2-酮,3-(1,1-二甲基乙基)-5,6-二氢-5-苯基-,(R)- 2H-1,3-恶嗪 2H-1,2-恶嗪 2-异丙基-4,4,6-三甲基-4H-1,3-恶嗪 2-(二甲基氨基)-4-苯基-4H-1,3-恶嗪-5-甲醛 2,4,4-三(三氟甲基)-6-全氟丁基-1,3,5-恶二嗪 (5S)-5,6-二氢-6,6-二甲基-5-苯基-2H-1,4-恶嗪-2-酮 3-(triethylsilyl)-2,5-dihydrofuran 4,4,6-trimethyl-2-propyl-4H-[1,3]oxazine 3-methyl-6,7,8,8a-tetrahydro-5H-cyclohepta[d]isoxazole 2,4-Dicyan-6-methyl-1,3-oxazepin 2,4-Dicyan-1,3-oxazepin 4-tert-Butyl-2,4,6-trimethyl-4H-pyran 3-(4,4,6-trimethyl-4H-[1,3]oxazin-2-yl)-propionitrile 4,4,6-Trimethyl-2-isopropenyl-1,3,4-oxazin 4a,7a-dihydro-4a,6-dimethyl-3-phenyl-4H-furo<2,3-e>-1,2-oxazine 3-methyl-1,4,6,9-tetraoxa-2-aza-5λ5-phospha-spiro[4.4]non-2-ene 6,8-Diethyl-1,1,2,2,3,3-hexafluoro-5-oxa-7,9-diaza-spiro[3.5]nona-6,8-diene (R)-4-Ethyl-3-((4S,5S)-4-methoxymethyl-5-phenyl-4,5-dihydro-oxazol-2-yl)-4H-pyridine-1-carboxylic acid methyl ester 4-Phenyl-2-pyrrolidin-1-yl-4,5-dihydro-furan-3-carbonitrile (S)-4-Ethyl-3-((4S,5S)-4-methoxymethyl-5-phenyl-4,5-dihydro-oxazol-2-yl)-4H-pyridine-1-carboxylic acid methyl ester (3S)-5-methyl-3-propan-2-yl-2,3-dihydro-1,4-oxazin-6-one dimethyl[η(10)-2,4-cyclopentadien-1-ylidene(dimethylsilylene)(3,4-di-tert-butyl-2,4-cyclopentadien-1-ylidene)]zirconium tert-butoxymethyl[η(10)-2,4-cyclopentadien-1-ylidene(dimethylsilylene)(3,4-di-tert-butyl-2,4-cyclopentadien-1-ylidene)]zirconium 2-Trimethylsilyl-4-methyl-4H-pyran methyl 3-methyl-6-trimethylsilylcyclohexa-1,4-dienecarboxylate 5-methyl-3-phenyl-(3ar,6ac)-3a,6a-dihydro-furo[2,3-d]isoxazole 2-methyl-4-chloro-3,6-dihydro-1,2-oxazine 4-n-butyl-3-<(N,N-diethylamino)methyl>-4,6-dimethyl-4H-pyran 3,5-diphenyl-(3ar,4at,7at,9ac)-3a,4a,7a,9a-tetrahydro-cyclohepta[2,1-d;4,5-d']diisoxazol-4-one 2-methyl-5-chloro-3,6-dihydro-1,2-oxazine 4,4-Di-tert-butyl-3-methyl-4H-<1,2>oxazet-N-oxid 6H-Pyrano[3,4-c]pyridine 6-ethoxy-3-phenyl-4-(trimethylsilylethynyl)-6H-1,2-oxazine 5,5-Dimethyl-2-oxazolin-4-spiro-3'-(1'-pyrrolin)